SCHEMBL5212423

SCHEMBL5212423

CCOP(=O)(Cc1ccc(NC(=O)CCc2oc(-c3n[nH]c4ccccc34)nc2-c2ccc(Cl)cc2)cc1)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 2/20 0.40
THRB P10828 2/20 0.40
HTT P42858 1/20 0.40
NAMPT P43490 3/20 0.39
ROCK1 Q13464 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 2/20 0.37
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GLA P06280 1/20 0.37
MAPK1 P28482 1/20 0.37
GAA P10253 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
NPY5R Q15761 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5214835 0.86 MAPT (0.40) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5213177 0.84 MAPT (0.40) MAPTMEN1KMT2ALMNATHRB
SCHEMBL5212418 0.84 MAPT (0.43) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5207021 0.83 MAPT (0.44) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL5207604 0.83 TP53 (0.47) MAPTMEN1KMT2ALMNAHTT
SCHEMBL5211940 0.83 MAPT (0.45) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5208499 0.83 YES1 (0.41) MAPTMEN1KMT2ALMNATHRB
SCHEMBL5215008 0.82 MAPT (0.41) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5207445 0.82 MEN1 (0.49) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5211339 0.82 MAPT (0.47) MAPTMEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPT 3958/4885MEN1 1626/4885KMT2A 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.